医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Foldax, Inc. Receives Full Ownership Rights to Proprietary Polymer Patent Portfolio

2023年05月11日 PM09:00
このエントリーをはてなブックマークに追加


 

SALT LAKE CITY

Foldax® Inc. today announced that it has executed an agreement with Australia’s national science agency, CSIRO, for full ownership of a polymer technology patent family. Foldax has incorporated the polymer technology into its LifePolymer™ materials platform and has conducted testing, which indicates the materials are compatible with blood, with low adherence of proteins, cells, and calcification. This LifePolymer material characteristic makes it highly biocompatible with the human body and extremely durable, which may be ideal for certain medical devices.

Foldax’s initial development with the patented LifePolymer material is for its portfolio of TRIA™ heart valves, which combines the polymer material with valve leaflet design intended to avoid calcification, withstand stresses and strains without failure, and restore patient quality of life without lifelong use of anticoagulant medication.

The LifePolymer technology has undergone extensive biological safety testing that has been included in Foldax’s regulatory filings to the FDA. The TRIA biopolymer heart valve is the first polymer valve ever to receive FDA approval for human studies in both aortic and mitral positions.

“While we believe LifePolymer is ideal for heart valves, we are also excited about the possibility of its application to other medical devices,” said Gregory D. Casciaro, Foldax CEO. “The biocompatible and durable material properties of LifePolymer may make it potentially ideal for drug delivery, orthopedics, glucose monitoring, cardiac cannula, blood pumps, blood oxygenation circuits, vascular, stent coverings, electrophysiology, and non- medical coatings.”

In the case of heart valves, the LifePolymer properties also enable TRIA valves to be the first and only valve robotically manufactured, reducing variability, and allowing for high precision, repeatability, and quality, while substantially improving the economics of manufacturing. Robotic manufacturing could potentially be incorporated in the production of other medical devices designed from LifePolymer, resulting in a robust supply chain and significantly lower manufacturing costs that could be transformative to expanding patient access to life-changing treatments.

The TRIA heart valve and LifePolymer technology are considered investigational and are not available for commercial sale in the U.S.

To learn more about Foldax, visit www.foldax.com.

Foldax Inc. is a medical device company committed to reinventing every aspect of the heart valve – from material to design to manufacturing – to develop surgical and transcatheter valves designed to last a lifetime addressing historical tradeoffs.

Foldax investors include Angel Physicians Fund, Biostar Capital, Caltech, Glenview Capital, Kairos Ventures, Memorial Care Innovation Fund and Sayan Bioventures.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230511005031/en/

CONTACT

Michelle McAdam, Chronic Communications, Inc.

michelle@chronic-comm.com

(310) 902-1274

同じカテゴリーの記事 

  • Rusan Pharma’s API Plant in Ankleshwar Receives (India) USFDA GMP Approval
  • Stonepeak to Acquire Arvida Group
  • European Medicines Agency Accepts Deciphera’s Marketing Authorization Application for Vimseltinib for Treatment of Patients with Tenosynovial Giant Cell Tumor (TGCT)
  • JCR Pharmaceuticals Highlights Innovative Gene Therapy Research at the 7th International Forum of Lysosomal Disorders
  • Equillium Announces Second Quarter 2024 Estimated Cash and Investments Balance